The Thrombophilia Program is one of eight national pilot programs supported by the Centers for Disease Control and Prevention. The center also participates in the Antiphospholipid Syndrome Collaborative Registry and the Women’s Initiative in Hemostatic Disorders.
This program provides close clinical and research collaborative efforts between clinicians and investigators in multiple subspecialties, including the Departments of Medicine, Surgery, Obstetrics and Gynecology, Radiology, and Pediatrics.
Opportunities exist to rotate through the Hemostasis and Thrombosis Laboratory and interact with programs in the Department of Pathology.
Learn more about the Duke Hemostasis and Thrombosis Center and see our clinical research page.
Administration
- Director: Thomas L. Ortel, MD, PhD (Hematology)
- Co-director: Andra H. James, MD (Maternal-Fetal Medicine)
Basic Research Programs Investigators
The following investigators provide research opportunities for basic scientific investigations into normal and abnormal hemostatic mechanisms (partial list):
- Gowthami Arepally, MD: Molecular basis of heparin-induced thrombocytopenia
- Maureane Hoffman, MD, PhD: Cell-based model of hemostasis
- Michael Kelley, MD: Genetics of hereditary macrothrombocytopenias
- Jeffrey H. Lawson, MD, PhD: Immunologic consequences of thrombin exposure
- Thomas L. Ortel, MD, PhD: Structure-function relationships of coagulation factor VIII
- Claude A. Piantadosi, MD: Coagulation blockade in acute lung injury
- Chris Rusconi, PhD, and Bruce Sullenger, PhD: Aptamers as coagulation inhibitors